STAT+: Pharmalittle: Pfizer Covid-19 vaccine to generate $26 billion in 2021 sales; EMA reviews Sinovac Covid-19 vaccine

Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like a pleasant morning to lift the spirits. A cool breeze and warm sun are enveloping the Pharmalot campus as we hunker down and sift through our ever-growing to-do list. A familiar exercise, yes? Well, time to get cracking. So please join us for a daily ritual — a few cups of stimulation — and do keep us in mind if you hear something fascinating. Meanwhile, here are your tidbits. Dig in and have a grand day. …

Pfizer (PFE) significantly increased revenue projections from its Covid-19 vaccine for the year, as sales from the shot over the first three months of 2021 lifted the company to a stronger quarterly profit, The Wall Street Journal says. The vaccine contributed $3.5 billion in revenue in the first three months of 2021 as the U.S. vaccination campaign kicked into high gear. Over the course of the full year, Pfizer now expects the vaccine to generate $26 billion in sales, up from an earlier forecast of $15 billion.

Continue to STAT+ to read the full story…